. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Most Consult your doctor for more details. Criteria for grading on the CTCAE scale vary by toxicity, however by convention, grade 1 typically refers to asymptomatic or mild symptoms not requiring intervention, grade 2 refers to moderate symptoms that interfere somewhat with daily function and where some intervention may be indicated, and grade 3 refers to severe symptoms that interfere . C- Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. 1192 0 obj
<>/Filter/FlateDecode/ID[]/Index[1186 14]/Info 1185 0 R/Length 52/Prev 116257/Root 1187 0 R/Size 1200/Type/XRef/W[1 2 1]>>stream
Use Caution/Monitor. An official website of the United States government. Use Caution/Monitor.elagolix will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Bone marrow biopsy was negative. anastrozole will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for adverse reactions. This site needs JavaScript to work properly. The CARTOX-10 questionnaire is a new tool proposed to prospectively assess overall cognitive function that could not be used in this retrospective study. palifermin increases toxicity of brentuximab vedotin by Other (see comment). Monitor Closely (1)saquinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. An electrocardiogram (ECG) was obtained, which was unremarkable, showing normal sinus rhythm. Use Caution/Monitor. Currently there is very little data in the literature in regard to the clinical manifestations and characteristics of patients taking brentuximab and the potential development of acute severe pulmonary toxicity, as well as the appropriate therapeutic approach, making this particular case of successful treatment and resolution unique. Monitor Closely (1)trastuzumab, brentuximab vedotin. Monitor patients for adverse reactions. Events graded as NT by CTCAE, but not mCRES and ASTCT. By comparison, the expert regrading of the 62 patients identified as having NT in the FDA label yielded 50 patients (45.0%) with NT, including 34 patients (30.6%) with grade 1/2, 11 patients (9.9%) with grade 3, and 5 patients (4.5%) with grade 4 NT. Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate approved to treat classical Hodgkin lymphoma (HL). Monitor or titrate P-gp substrate dose if coadministered. Monitor Closely (1)ritonavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. 0000007690 00000 n
For 47 patients without CRS, the CTCAE, mCRES, and ASTCT systems identified a rate of grade 3 or higher NT of 10.6%, 8.5%, and 8.5%, respectively (Table 6). After reconstitution (see section 6.6), each mL contains 5 mg of brentuximab vedotin. Access your plan list on any device mobile or desktop. Consider dose reduction of sensitive P-gp substrates. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.